Options Activity: Market observers noted aggressive buying of put option contracts for Alkermes shares with an October expiration. This move drew attention as it reflected positioning ahead of potential volatility in the shares. Discussions focused on the implications for near-term price action.
Chart Analysis: Investors shared technical breakdowns of Alkermes price trends on social media. Key support levels and moving averages featured prominently in the commentary. Participants examined how recent trading patterns align with broader sector movements.
Note: This discussion summary was generated from an AI condensation of post data.
Alkermes Insider Trading Activity
Alkermes insiders have traded $ALKS stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $ALKS stock by insiders over the last 6 months:
- CRAIG C. HOPKINSON (EVP R&D, Chief Medical Officer) has made 0 purchases and 7 sales selling 54,000 shares for an estimated $2,318,922.
- NANCY LYNN MD SNYDERMAN sold 44,472 shares for an estimated $2,239,076
- SAMUEL JOSEPH PARISI (VP, Finance (Interim PAO)) sold 16,217 shares for an estimated $687,007
- DAVID JOSEPH GAFFIN (EVP, CLO, Alkermes, Inc.) has made 0 purchases and 6 sales selling 12,204 shares for an estimated $531,768.
- CHRISTIAN TODD NICHOLS (SVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 7,576 shares for an estimated $372,936.
- CHRISTOPHER I WRIGHT sold 2,000 shares for an estimated $90,200
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Alkermes Congressional Stock Trading
Members of Congress have traded $ALKS stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ALKS stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $50,000 on 07/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Alkermes Hedge Fund Activity
We have seen 231 institutional investors add shares of Alkermes stock to their portfolio, and 216 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,335,117 shares (+inf%) to their portfolio in Q2 2026, for an estimated $122,348,455
- AMERICAN CENTURY COMPANIES INC removed 2,117,864 shares (-34.9%) from their portfolio in Q2 2026, for an estimated $110,965,484
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,072,752 shares (+44.4%) to their portfolio in Q2 2026, for an estimated $108,601,841
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,450,841 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $51,301,737
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,368,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $71,676,360
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC added 1,327,938 shares (+217.7%) to their portfolio in Q2 2026, for an estimated $69,577,311
- HOLOCENE ADVISORS, LP added 1,284,146 shares (+55.4%) to their portfolio in Q2 2026, for an estimated $67,282,829
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Alkermes Analyst Ratings
Wall Street analysts have issued reports on $ALKS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 05/06/2026
To track analyst ratings and price targets for Alkermes, check out Quiver Quantitative's $ALKS forecast page.
Alkermes Price Targets
Multiple analysts have issued price targets for $ALKS recently. We have seen 9 analysts offer price targets for $ALKS in the last 6 months, with a median target of $50.0.
Here are some recent targets:
- Uy Ear from Mizuho set a target price of $65.0 on 07/02/2026
- Jason Gerberry from B of A Securities set a target price of $38.0 on 06/29/2026
- Benjamin Burnett from Wells Fargo set a target price of $65.0 on 06/29/2026
- Ami Fadia from Needham set a target price of $61.0 on 06/24/2026
- Joseph Thome from TD Cowen set a target price of $50.0 on 06/22/2026
- Leonid Timashev from RBC Capital set a target price of $56.0 on 06/09/2026
- Joel Beatty from Baird set a target price of $48.0 on 05/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
